Cardiovascular Today—June 18, 2026

LucidQuest

2 hours ago

This week’s Cardiovascular update highlights regulatory clearances, device innovation, clinical trial expansion, long-term follow-up data, acquisition activity, and evolving patient-care considerations across stroke, structural heart, and coronary disease.

In Today’s Newsletter

Dive deeper

⚠️ Abbott recalls Merlin PCS 3650 monitoring software [1] [US • 12 Jun 2026]

https://cardiovascularbusiness.com/topics/clinical/heart-rhythm/abbott-recalls-heart-device-monitoring-system-due-malfunction-risk
Context: Recall involves Merlin PCS 3650 systems used to interrogate and program implantable cardiac devices.
Key point: Abbott identified a software malfunction that may interrupt telemetry during testing of certain Aveir leadless pacemakers; a software update is being deployed.
Implication: Introduces a device-management issue that may require operational updates and customer remediation.

🤝 Medtronic completes Scientia Vascular acquisition [2] [15 Jun 2026]

https://cardiovascularbusiness.com/topics/clinical/vascular-endovascular/medtronic-completes-550m-acquisition-neurovascular-company
Context: Scientia Vascular develops guidewires and catheters designed for neurovascular procedures and stroke treatment.
Key point: Medtronic finalized its acquisition of Scientia Vascular in a deal valued at approximately $550 million.
Implication: Signals pipeline investment and modality expansion.

🧠 Penumbra gains FDA clearance for Thunderbolt stroke device [3] [US • 12 Jun 2026]

https://cardiovascularbusiness.com/topics/clinical/vascular-endovascular/fda-clears-new-computer-assisted-device-removing-clots-stroke-patients
Context: Thunderbolt is a computer-assisted vacuum thrombectomy system for acute ischemic stroke.
Key point: FDA cleared Thunderbolt, which Penumbra describes as the first approved computer-assisted vacuum thrombectomy device for stroke in the US.
Implication: May influence treatment workflows as clinicians evaluate new clot-removal technologies.

❤️ Anteris advances PARADIGM trial of DurAVR valve [4] [France • 15 Jun 2026]

https://cardiovascularnews.com/paradigm-trial-of-duravr-tavi-valve-to-begin-enrolling-at-french-centres/
Context: PARADIGM is a randomized controlled trial comparing DurAVR with commercially available TAVI systems.
Key point: French regulatory authorization allows patient enrolment to begin at French centres.
Implication: May influence prescriber choice and payer reviews pending full data.

👩‍⚕️ IPEC2 highlights diagnostic barriers for women with cardiovascular disease [5] [15 Jun 2026]

https://cardiovascularnews.com/ipec2-study-sheds-light-on-experiences-of-women-with-cardiovascular-disease/
Context: Patient-led qualitative research included women across multiple countries with cardiovascular conditions and risk factors.
Key point: Findings suggest delays in care-seeking, symptom recognition challenges, and perceived bias in diagnosis and treatment pathways.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🩺 Teleflex reports four-year Freesolve scaffold data [6] [15 Jun 2026]

https://cardiovascularnews.com/four-year-data-show-favourable-safety-and-performance-of-resorbable-magnesium-scaffold/
Context: BIOMAG-I enrolled 116 patients and evaluated the Freesolve resorbable magnesium scaffold.
Key point: Four-year follow-up showed favourable safety and performance, according to the company.
Implication: May influence prescriber choice and payer reviews pending full data.

🔊 Cardiawave begins routine use of Valvosoft in Europe [7] [Europe • 16 Jun 2026]

https://cardiovascularnews.com/first-routine-cases-performed-using-ultrasound-treatment-for-aortic-stenosis/
Context: Valvosoft is a non-invasive ultrasound therapy for severe symptomatic aortic stenosis and received CE marking in 2025.
Key point: The first routine clinical cases have been performed in Europe following commercial rollout.
Implication: May expand treatment options for patients who are not immediate candidates for valve replacement.

💥 First patient enrolled in coronary pulsatile IVL study [8] [Australia–New Zealand • 15 Jun 2026]

https://cardiovascularnews.com/first-patients-enrolled-in-study-of-pulsatile-ivl-in-coronary-artery-disease/
Context: POWER CAD I is a first-in-human feasibility study of the Pulse IVL system in calcified coronary artery disease.
Key point: Amplitude Vascular Systems, now part of Stryker, enrolled the first patient in the study.
Implication: May influence prescriber choice and payer reviews pending full data.

Why it matters

Neurovascular innovation remains active, with both Medtronic’s acquisition activity and Penumbra’s regulatory progress focused on stroke care.
Structural heart companies continue to expand clinical evidence generation, including DurAVR and Valvosoft programs.
Coronary calcium modification remains a competitive area, with new IVL approaches entering early clinical evaluation.
Long-term follow-up data for bioresorbable scaffold technologies may help inform future comparative studies versus permanent implants.
Patient-experience research continues to highlight gaps in cardiovascular diagnosis and care pathways for women.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

🎯 Catch up on the Top Cardiovascular news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What was recalled by Abbott?

Abbott recalled Merlin PCS 3650 software because of a telemetry malfunction risk during certain pacemaker testing scenarios. The company is addressing the issue through a software update rather than device returns. [1]

Why did Medtronic acquire Scientia Vascular?

Medtronic stated that Scientia’s neurovascular access technologies complement its existing stroke and neurovascular portfolio, supporting more integrated procedural solutions. [2]

What is Thunderbolt from Penumbra?

Thunderbolt is a computer-assisted vacuum thrombectomy device cleared by the FDA for acute ischemic stroke treatment. Penumbra positions it as a new approach to clot removal. [3]

What is the PARADIGM trial evaluating?

PARADIGM is a randomized study comparing the DurAVR transcatheter heart valve with commercially available TAVI systems in severe calcific aortic stenosis. [4]

What did the IPEC2 study find about women and cardiovascular disease?

Participants reported delayed diagnosis, symptom recognition challenges, and perceived bias during care. The study was qualitative and focused on patient experiences. [5]

What is Valvosoft designed to do?

Cardiawave’s Valvosoft uses focused ultrasound to treat severe symptomatic aortic stenosis without surgery or implantation, targeting restoration of valve leaflet mobility. [7]

Entities / Keywords

Abbott, Merlin PCS 3650, Aveir leadless pacemaker, Medtronic, Scientia Vascular, neurovascular devices, Penumbra, Thunderbolt, computer-assisted vacuum thrombectomy (CAVT), acute ischemic stroke, Anteris Technologies, DurAVR, PARADIGM trial, TAVI, Global Heart Hub, IPEC2, women’s cardiovascular health, Teleflex, Freesolve, resorbable magnesium scaffold (RMS), BIOMAG-I, Cardiawave, Valvosoft, aortic stenosis, Stryker, Amplitude Vascular Systems, Pulse IVL, pulsatile intravascular lithotripsy (PIVL), POWER CAD I.